Navigation Links
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients

Abbott Will Register and Make the New Lower-Strength lopinavir/ritonavir Tablet Available in More Than 150 Countries to Support Broad Access for the

More Than 2 Million Children Living with HIV Worldwide

ABBOTT PARK, Ill., Nov. 12 /PRNewswire-FirstCall/ -- Abbott today announced that it has received U.S. Food and Drug Administration (FDA) approval for a new lower-strength tablet formulation of its leading HIV protease inhibitor, Kaletra(R) (lopinavir/ritonavir), which is also marketed as Aluvia(R) (lopinavir/ritonavir) in developing countries. The lower-strength Kaletra tablets will be available in the U.S. this month.

Abbott is awaiting EMEA marketing authorization for the Kaletra/Aluvia lower-strength tablets. Upon EMEA marketing authorization, Abbott intends to register this new tablet formulation in more than 150 countries. The soft gel capsule formulation of LPV/r is the most widely registered protease inhibitor in the world. The original tablet formulation is already available in 93 countries and Abbott is awaiting approval in an additional 45 countries for this formulation.

Approval of this lower-strength Kaletra tablet represents an important step in Abbott's ongoing commitment to the global fight against HIV because:

-- The tablets do not require refrigeration and can be taken with or

without a meal -- an important advance in delivering HIV medicine to

children in developing countries.

-- The World Health Organization (WHO) estimates 2 million children were

living with HIV/AIDS in sub-Saharan Africa at the end of 2006.

-- The new lower-strength tablets are smaller in size than original

Kaletra tablets and contain the same proven active ingredients as

Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is

approved for children weighing 15kg or more who are able to swallow

the intact tablet.

-- The FDA approval expands available options for using the first and

only co-formulated protease inhibitor tablet to treat children with


"HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world," said Scott Brun, M.D., divisional vice president, infectious diseases and renal development, Global Pharmaceutical Research and Development, Abbott. "Abbott developed a lower-strength tablet formulation of Kaletra to give physicians an innovative treatment option to help curb the impact of HIV infection in children."

The price of the recently approved lower-strength tablet will be half the price of the original tablet in the developing world.

About Kaletra Lower-Strength Tablets

The new tablet formulation will complement Kaletra oral solution, which has been available for pediatric use since its approval in September 2000 in the United States. For pediatric patients, lower-strength Kaletra tablets will offer more dosing flexibility and contains 100mg of lopinavir and 25mg of ritonavir, compared with the original tablet strength of 200mg of lopinavir and 50mg of ritonavir, most commonly used by adults.

About Abbott's Commitment to Fighting HIV/AIDS

HIV/AIDS is a global problem that demands shared commitment and shared responsibility. Abbott is committed to working with governments, multilateral organizations, nongovernmental organizations (NGOs) and civil society to expand access to HIV/AIDS treatments around the world.

Abbott has made significant investments in expanding manufacturing capacity to meet the growing demand for HIV treatment in developing countries.

Abbott's lopinavir/ritonavir formulations are among the lowest-priced protease inhibitors in the developing world. Abbott has been providing its HIV medicines at a price of $500 per adult patient per year in all African and least developed countries (LDCs) since 2002, making these medicines more affordable than any generic copies.

Abbott and the Abbott Fund are investing more than $100 million in developing countries through the Abbott Global AIDS Care programs focusing on four areas: strengthening health care systems; helping children affected by HIV/AIDS; preventing mother-to-child transmission of HIV; and expanding access to testing and treatment. Abbott and Abbott Fund have also announced several efforts to expand access to treatment and care for children living with HIV/AIDS, including an additional investment of $12 million in grants and product donations this year.

Background on HIV in Children

According to the WHO, an estimated 2.3 million children under the age of 15 worldwide were living with HIV/AIDS in 2006; a vast majority -- 2 million children with HIV/AIDS -- was living in Africa. Based on 2004 Centers for Disease Control and Prevention (CDC) data for 33 states, an estimated 3,336 children under the age of 13 were living with HIV/AIDS in the United States. While the number of pediatric AIDS cases has decreased overall in the U.S., the risk among African-American and Hispanic infants and children is of special concern. Among U.S. children living with AIDS, 63 percent are African-American, 21.6 percent are Hispanic, and 14.2 percent are Caucasian. The U.S. Department of Health & Human Services (HHS) and the WHO recommend lopinavir/ritonavir for the treatment of children with HIV.


KALETRA(R) (lopinavir/ritonavir) is a human immunodeficiency virus-1 (HIV-1) protease inhibitor. KALETRA is always used in combination with other anti-HIV-1 medicines for the treatment of HIV-1 infection. KALETRA is a combination of two medicines, lopinavir and ritonavir. KALETRA is for adults and for children age 6 months and older.

Important Safety Information

KALETRA does not cure HIV-1 infection or AIDS and does not reduce the risk of passing HIV-1 to others.

KALETRA must not be taken by patients who have had an allergic reaction to KALETRA or any of its ingredients.

Taking KALETRA with certain drugs can cause serious problems or death. KALETRA must not be taken with dihydro-ergotamine, ergonovine, ergotamine, or methylergonovines such as Cafergot(R), Migranal(R), D.H.E. 45(R), ergotrate maleate, and methergine, as well as Halcion(R) (triazolam), Orap(R) (pimozide), Propulsid(R) (cisapride), or Versed(R) (midazolam).

KALETRA must not be taken with rifampin, also known as Rimactane(R), Rifadin(R), Rifater(R), or Rifamate(R); St. John's wort (Hypericum perforatum); Mevacor(R) (lovastatin), or Zocor(R) (simvastatin).

There are drug-drug interactions with the potential for risk of serious or life-threatening side effects. Alterations in dose, increased monitoring of drug levels in the blood, or increased observations for side effects may be recommended when KALETRA is taken with: Lipitor(R) (atorvastatin), Crestor(R) (rosuvastatin), Viagra(R) (sildenafil), Cialis(R) (tadalafil), Levitra(R) (vardenafil), oral contraceptives ("the pill") or the contraceptive patch, Mycobutin(R) (rifabutin), inhaled Flonase(R) (fluticasone), metronidazole, or disulfiram. Patients should talk with their doctor about all medicines they are taking or planning to take, including those without a prescription and herbal products.

KALETRA should not be given once-daily in combination with Sustiva(R) (efavirenz), Viramune(R) (nevirapine), Agenerase(R) (amprenavir), fosamprenavir, Viracept(R) (nelfinavir), phenobarbital, phenytoin (Dilantin(R)) or carbamazepine (Tegretol(R)).

Patients and/or their care providers should pay special attention to accurate administration of the KALETRA dose to reduce the risk of accidentally giving too much or too little medicine.

The most commonly reported side effects of moderate severity that are thought to be drug related are abdominal pain, abnormal bowel movements, diarrhea, feeling weak/tired, headache, and nausea. Children taking KALETRA may sometimes get a skin rash. Other side effects may occur.

Pancreatitis and liver problems, which can be fatal, have been reported in patients receiving KALETRA. Patients should tell their doctor if they have nausea, vomiting, or abdominal pain, which may be signs of pancreatitis, or if they have or have had liver disease such as Hepatitis B or C.

Some patients have had large increases in triglycerides and cholesterol. Changes in body fat have been seen in some patients taking anti-HIV therapy. The long-term health effects of these conditions are not known at this time. Diabetes and high blood sugar have occurred in patients taking protease inhibitors such as KALETRA.

Some patients with hemophilia have increased bleeding with protease inhibitors.

The effects of KALETRA on pregnant women or their unborn babies are not known. Mothers taking KALETRA should not breast-feed.

All strengths of KALETRA tablets should be swallowed whole and not chewed, broken, or crushed.

KALETRA tablets should be stored at room temperature. Exposure of this product to high humidity outside the pharmacy container for longer than 2 weeks is not recommended.

Refrigerated KALETRA oral solution remains stable until the expiration date printed on the label. If stored at room temperature up to 77F (25C), KALETRA oral solution should be used within 2 months.

Avoid exposure to excessive heat. For full prescribing information visit

Abbott and HIV

Abbott has been a leader in HIV/AIDS research since the early years of the epidemic. In 1985, the company developed the first licensed test to detect HIV antibodies in the blood and remains a leader in HIV diagnostics. Abbott retroviral and hepatitis tests are used to screen more than half of the world's donated blood supply. Abbott has developed two protease inhibitors for the treatment of HIV.

Expanding on its scientific contributions, Abbott and Abbott Fund have invested more than $100 million in developing countries to improve the lives of people affected by HIV/AIDS through programs targeting critical areas of need, including strengthening health care systems and supporting children affected by HIV/AIDS and advancing HIV testing and treatment. For more information on Abbott's HIV/AIDS programs, please visit and

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in ... the orthodontic system that uses clear, plastic aligners. This alternative to braces has ... teeth, which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are ...
(Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the ... walks of life to save money on the high cost of their prescription ... per medication, individuals and families can receive their medications delivered direct from over ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... one of the oldest and largest recreational dispensaries in Colorado, says the latest ... business is growing rapidly and maturing into a legitimate industry. , Last ...
Breaking Medicine News(10 mins):
... The Ensign Group, Inc. (Nasdaq: ENSG ... Healthcare Center, a 150-bed skilled nursing facility in ... 2009. The facility has been renamed Southland Rehabilitation ... is a strategic acquisition, and adds to our ...
... 5 The Ensign Group, Inc. (Nasdaq: ... acquired Cabrillo Care Center, a 156-bed skilled nursing ... was effective January 1, 2009. The facility has ... )"We are excited to extend ...
... Properties in Denver, Colorado , ... Newport Beach, Calif ... firm, LFC Group of Companies, launched a new auction campaign of ... website, Freedom Realty Exchange ( ). The auction, a builder ...
... January 30th noon to 5PM in our new Hyundai Dealer showroom at 271 Main ... first 50 to donate blood. , ... Wilmington, MA (PRWEB) January 5, 2009 -- Bill Dube ... as the recent ice & snow storms that hit New England have canceled blood ...
... adopted research informatics platform, OnCore®, achieved another ... a world-class multidisciplinary research organization. At the ... Institute for Clinical and Translational Research (UWICTR) ... research data collection and administration needs. OnCore ...
... -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... retail,drugstore chain in China based on the number ... Mr. Ian Wade, a retail industry veteran,with an ... Executive Officer.,Concurrently, the Company announced the appointment of ...
Cached Medicine News:
(Date:10/9/2015)... Lilly and Company (NYSE: LLY ) and Locemia ... Locemia,s intranasal glucagon, a potential treatment for severe hypoglycemia ... which is currently in Phase III clinical trial testing, ... hypoglycemia. --> --> ... formulation that is delivered in an emergency situation using ...
(Date:10/9/2015)... , Oct. 9, 2015 Regardless ... Device environments, corporate communications is perpetually evolving. Due ... and professionals must continuously adjust their business-to-business (B2B) ... these adjustments is difficult, but also critical as ... options. --> ...
(Date:10/9/2015)... -- Regulatory affairs groups within medical device organizations face a ... These specialized groups are charged with ensuring that their ... to the development and marketing of medical device products. While ... their own internal effectiveness and efficiencies to remain productive and ... --> Optimal resourcing and staffing help ...
Breaking Medicine Technology:
... kids are outside playing soccer, baseball, or lacrosse, jumping rope, ... know, there is a trip to the emergency room. Childhood ... is the refined work of physicians and hospitals but it ... while injured. A common problem parents face is how to ...
... Mass., May 15, 2012  IntelligentMDx (IMDx) announced today that ... qualitative in vitro diagnostic test designed for ... (GBS) for use in screening pregnant women and those ... GBS is responsible for life-threatening bacterial infections in newborns, ...
Cached Medicine Technology:
ArcticTemp Upright Freezer -20C. Thick wall insulation keeps your samples colder. Reversible door with magnetic gaskets. 2 shelves and a wire basket. Heavy duty compressor with 5 year warranty....
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... a portable system for routine pH, mV ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... automatic buffer recognition for five buffers (pH ...
... The F 265 is a highly accurate portable, ... and temperature measurements. Temperature compensated pH results can ... (ATC) or a 3-in-1 electrode. • This GLP/GMP ... to a printer or a computer. Up to ...
Medicine Products: